Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SQLE | Q14534 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10596935 | 1.00 | KMT2A (0.39) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL10542200 | 0.97 | — | — | |
| SCHEMBL10543714 | 0.95 | KMT2A (0.39) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL4574808 | 0.89 | — | — | |
| SCHEMBL8078444 | 0.83 | KMT2A (0.50) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL31399505 | 0.78 | DGKA (0.44) | CYP3A4ALOX15ALDH1A1TSHR | |
| SCHEMBL31399494 | 0.78 | DGKA (0.44) | CYP3A4ALOX15ALDH1A1TSHR | |
| SCHEMBL18026775 | 0.78 | SQLE (0.44) | KMT2AMEN1CYP3A4ALOX15SQLE | |
| SCHEMBL230243 | 0.77 | — | — | |
| SCHEMBL9633770 | 0.77 | KMT2A (0.67) | KMT2AMEN1CYP3A4ALOX15SQLE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070194277-A1 | LIGHT EMITTING POLYMER | O'NEILL MARY | 2007-08-23 | — | — | US | disclosed |
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | KMT2A 2143/4885MEN1 4484/4885CYP3A4 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.